ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMDespesas comerciais, gerais e administrativas148.1 M121.8 M124.8 M106.8 M103 M100.5 M435.1 MPesquisa e desenvolvimento———————Lucro operacional-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-3.4 M-355.9 MLucro não operacional, total2.5 M-5.6 M-17.1 M2.5 M1.1 M10.2 M-3.3 MDespesa com juros, líquida de juros capitalizados———————Receitas não operacionais, líquidas das despesas com juros-3.7 M-5.6 M-19.9 M-2.6 M1.1 M9.7 M-11.7 MReceitas/despesas incomuns6.2 M02.8 M5.1 M0500 K8.4 MLucro antes dos impostos-74.9 M-548 M-370.7 M-28.7 M-35.6 M-12.3 M-447.3 MParticipação no lucro———————Impostos-1 M14.9 M4.2 M-12.8 M-3.1 M11.3 M-400 KParticipação de minoritários———————Outras receitas/despesas após impostos-4.6 M-300 K-2 M100 K-2.3 M-400 K-4.6 MLucro líquido antes das operações descontinuadas-73.9 M-562.9 M-374.9 M-15.9 M-32.5 M-23.6 M-446.9 MOperações descontinuadas12.7 M0000——Lucro líquido-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-23.6 M-446.9 MAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-23.6 M-446.9 MLucro básico por ação-0.68-6.25-4.14-0.17-0.25-0.25-4.81Lucro diluído por ação-0.68-6.25-4.14-0.17-0.25-0.25-4.81Número médio de ações básicas89.5 M————93.6 M—Ações diluídas89.5 M————93.6 M—EBITDA-34.8 M-500.6 M-310.7 M11 M5.7 M16.4 M-277.6 MEBIT-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-3.4 M-355.9 MCusto da receita556.1 M534.8 M576.8 M578.6 M529.4 M512.9 M2.2 BOutros componentes do custo556.1 M534.8 M576.8 M578.6 M529.4 M512.9 M2.2 BAmortização e depreciação (fluxo de caixa)20.8 M19.5 M19.6 M19.6 M19.3 M19.8 M78.3 M
Fortrea Holdings Inc. - Common Stock
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.